John Bergan

John Bergan has over 28 years of experience in the pharmaceutical industry. John has held various positions, starting as a Bioanalytical Chemist at Eli Lilly in 1993. John then moved to Gilead Sciences as a Senior Research Associate in 2000, followed by a Manager Regulatory Affairs position at Catalyst Pharmaceutical Research in 2002. In 2003, they joined Amgen as a Senior Manager, Global Regulatory Affairs. In 2012, they became a Global Regulatory Team Leader at Bristol-Myers Squibb, and then a Senior Director at Genentech in 2014. In 2020, they joined Omeros Corporation as a Sr. Director, Regulatory Group Head, and most recently in 2021, they became Vice President, Head of Regulatory Affairs at Immune-Onc Therapeutics.

John Bergan received their Bachelor of Science (BS) in Chemistry from Purdue University in 1995. John then went on to obtain a Masters Certificate in Clinical Research Design and Management from the University of Southern California in 2011.